News and Announcements
SUDA Business Development Update and AGM Presentation
- Published November 17, 2015 4:12PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
17th November 2015
SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it is on track with its business development goals to sign licensing deals in FY2015/16 and to secure philanthropic funding for a second Phase III study of ArTiMist™ in paediatric malaria.
In early November, the management team attended the BIO-Europe international partnering conference, which was held in Munich, Germany; and also the Northern Australian Investment Forum on tropical diseases, which took place in Darwin. These events provided excellent opportunities for the Company to further advance its business development activities.
SUDA’s business development team met with 41 companies at the BIO-Europe event, comprising 24 first-time meetings and 17 ongoing dialogues with prospective partners. The most advanced discussions are at the stage of financial negotiation and span several of the companies’ first-in-class oral sprays in various territories.
To read the full announcement, please click on the link below.
To view the presentation, please click here.